Cardiovascular side effects of hypoglycemia

Homocysteine,C-reactive protein, and counter regulatory hormone changes in insulin-induced hypoglycemia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138811112587N3

Enrollment

Registered

2010-06-01

Start date

2008-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Homocystein, CRP and counter regulatory hormones evaluations in response to hypoglycemia. -

Interventions

Intravenous regular insulin 0.1-0.15 Unit/Kg.

Intravenous regular insulin 0.1-0.15 Unit/Kg

Eligibility

Sex/Gender

Male

Age

19 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusions Criteria: age 18–65 years, healthy individuals according to clinical and paraclinical assessments, BMI range of 19-30 kg/m2, written informed consent. Exclusions Criteria: anemia (hematocrit 1.5 mg/dl), and cardiovascular disease), central nervous system diseases including seizure disorder, defined diabetes mellitus, hypertension, concurrent infection, and fasting blood glucose=126 mg/dl.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum homocystein level. Timepoint: Baseline, and 30, 45, 60, 120, 240 after insulin injection. Method of measurement: Plasma HPLC.;Serum CRP level. Timepoint: Baseline, and 30, 45, 60, 120, 240 after insulin injection. Method of measurement: Plasma HPLC.	—

Secondary

Measure	Time frame
Blood Growth Hormone Level. Timepoint: Baseline, and 30, 45, 60, 120, 240 minutes after insulin injection. Method of measurement: Plasma HPLC.;Serum Cortisol. Timepoint: Baseline, and 30, 45, 60, 120, 240 minutes after insulin injection. Method of measurement: Plasma HPLC.;Serum norepinephrine level. Timepoint: Baseline, and 30, 45, 60, 120, 240 minutes after insulin injection. Method of measurement: Plasma HPLC.;Serum epinephrine level. Timepoint: Baseline, and 30, 45, 60, 120, 240 minutes after insulin injection. Method of measurement: Plasma HPLC.;Serum ACTH level. Timepoint: Baseline, and 30, 45, 60, 120, 240 minutes after insulin injection. Method of measurement: Plasma HPLC.	—

Measure

Time frame

Blood Growth Hormone Level. Timepoint: Baseline, and 30, 45, 60, 120, 240 minutes after insulin injection. Method of measurement: Plasma HPLC.;Serum Cortisol. Timepoint: Baseline, and 30, 45, 60, 120, 240 minutes after insulin injection. Method of measurement: Plasma HPLC.;Serum norepinephrine level. Timepoint: Baseline, and 30, 45, 60, 120, 240 minutes after insulin injection. Method of measurement: Plasma HPLC.;Serum epinephrine level. Timepoint: Baseline, and 30, 45, 60, 120, 240 minutes after insulin injection. Method of measurement: Plasma HPLC.;Serum ACTH level. Timepoint: Baseline, and 30, 45, 60, 120, 240 minutes after insulin injection. Method of measurement: Plasma HPLC.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ramin Heshmat

Endocrinology and Metabolism Research Center

emrc@tums.ac.ir+98 21 8822 0037

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026